{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:06:09Z","timestamp":1791446769670,"version":"4.3.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AG036778"],"award-info":[{"award-number":["K24AG036778"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL139671"],"award-info":[{"award-number":["R01HL139671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG058348"],"award-info":[{"award-number":["R21AG058348"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.healun.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T16:45:44Z","timestamp":1635180344000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies"],"prefix":"10.1016","volume":"41","author":[{"given":"Jan M.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonore","family":"Baughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-4631","authenticated-orcid":false,"given":"Hannah","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8351-9219","authenticated-orcid":false,"given":"Kevin J.","family":"Clerkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Raikhelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Uriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-8331","authenticated-orcid":false,"given":"Thomas H.","family":"Brannagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-3196","authenticated-orcid":false,"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Marboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-9368","authenticated-orcid":false,"given":"Maryjane A.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2021.10.007_bib0001","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0002","doi-asserted-by":"crossref","first-page":"e14028","DOI":"10.1111\/ctr.14028","article-title":"Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis","volume":"34","author":"Griffin","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0003","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","article-title":"Cardiac transplantation for amyloid heart disease: the United Kingdom experience","volume":"23","author":"Dubrey","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","article-title":"Outcomes after cardiac transplant for wild type transthyretin amyloidosis","volume":"102","author":"Rosenbaum","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.healun.2016.01.174","article-title":"Outcomes of heart transplantation for transthyretin-related amyloid cardiomyopathy","volume":"35","author":"Sabatino","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0006","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.healun.2021.10.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007931","article-title":"Durable mechanical circulatory support in patients with amyloid cardiomyopathy: Insights from INTERMACS","volume":"13","author":"Michelis","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.healun.2021.10.007_bib0008","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report \u2014 2019; focus theme: Donor and recipient size match","volume":"38","author":"Khush","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0009","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.healun.2013.08.006","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report\u20132013; focus theme: age","volume":"32","author":"Lund","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","article-title":"COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score","volume":"87","author":"Sletten","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.healun.2021.10.007_bib0011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0012","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/00007890-199804150-00010","article-title":"Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy","volume":"65","author":"Pomfret","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.10.007_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.23521","article-title":"Liver transplantation and transthyretin amyloidosis","volume":"47","author":"Benson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.healun.2021.10.007_bib0014","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1526924817715463","article-title":"Outcomes of patients with familial transthyretin amyloidosis after liver transplantation","volume":"27","author":"Banerjee","year":"2017","journal-title":"Prog Transplant"},{"key":"10.1016\/j.healun.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol"},{"issue":"15 suppl","key":"10.1016\/j.healun.2021.10.007_bib0016","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1212\/WNL.94.15_supplement.2240","article-title":"Rationale and design of NEURO-TTRansform, a phase 3 study to evaluate the efficacy and safety of AKCEA-TTR-LRx (ION-682884) in patients with hereditary transthyretin-mediated amyloid polyneuropathy (2240)","volume":"94","author":"Khella","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.healun.2021.10.007_bib0017","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/ene.12717","article-title":"Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy","volume":"22","author":"Treister","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.healun.2021.10.007_bib0018","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2021.10.007_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2021.10.007_bib0020","unstructured":"Agency EM. Tegsedi: EPAR - summary for the public. 2018; https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tegsedi-epar-product-information_en.pdf. Accessed March 22, 2021."},{"issue":"suppl_1","key":"10.1016\/j.healun.2021.10.007_bib0021","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1182\/blood-2019-129269","article-title":"Rationale and design of a phase 3 study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)","volume":"134","author":"Falk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.healun.2021.10.007_bib0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.healun.2021.10.007_bib0023","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.healun.2021.10.007_bib0024","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz","year":"2016","journal-title":"Amyloid"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249821025468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249821025468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:13:50Z","timestamp":1762355630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249821025468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1053249821025468"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2021.10.007","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}